FastForward Inn Ltd

Investee Company Update: EMMAC Life Sciences

RNS Number : 9646M
FastForward Innovations Limited
26 January 2021
 

FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End Investments

26 January 2021

FastForward Innovations Ltd ("FastForward" or, "FFWD")

 

Investee Company Update: EMMAC Life Sciences

 

FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, notes the following announcement released today concerning investee company EMMAC Life Sciences ('EMMAC'). FastForward has a 2.3% interest in the issued stock of EMMAC.

 

The announcement is set out below without material changes or adjustments.

 

EMMAC Life Sciences Group and Boiron selected for French Medical Cannabis trial

Only European Company selected by the French Agency for the Safety of Medicines and Health Products (ANSM)

 

26 January 2021, London. EMMAC Life Sciences Group ("EMMAC" or the "Group" or the "Company"), Europe's largest independent cannabis company, is pleased to announce that in partnership with Paris Euronext listed Boiron (BOI.PA), it has been selected by the French Agency for the Safety of Medicines and Health Products ("ANSM") as one of the suppliers for the forthcoming French Medical Cannabis trial.

 

The trial, the first of its kind in France, will allow 3,000 patients access to medical cannabis as a treatment option for certain indications; including chronic pain, epilepsy, oncology and spasticity; under tightly controlled conditions.  ANSM has selected EMMAC's 20/1 and 10/10 oral solutions as second-source treatments to be available to patients and healthcare professionals as part of the two year trial.

 

The partnership combines Boiron's unparalled expertise in plant-based medicine, with EMMAC's uniquely controlled European supply chain, from seed to patient, in order to deliver  pharmaceutical-grade cannabis medicines that meet the strict requirements of product quality, safety and traceability.

 

Valérie Lorentz-Poinsot, Chief Executive Officer of Boiron, said: "Participating in this trial is part of our project to provide patients in therapeutic impasse with effective solutions.  Medical cannabis is an important alternative treatment option for the future, particularly for the management of chronic and complex pain.  We are very pleased to partner with EMMAC Life Sciences Group in this project, and remain at the disposal of the ANSM."

 

Antonio Costanzo, Chief Executive Officer of EMMAC, said: "We are proud to have been selected to be part of this important trial.  Alongside Boiron, we are pleased to share our international experience to advance the industry's understanding of the benefits of medical cannabis.  The selection of our products by ANSM is testament to EMMAC's scientific knowledge and rigor, as well as our ability to provide products to the highest standards of compliance, safety and quality."

 

- Ends -

 

About EMMAC Life Sciences Group

EMMAC Life Sciences Group is Europe's largest independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC's vision is to bring the life-enhancing potential of cannabis to the people who need it. For more information about EMMAC, please visit https://www.emmac.com/ .  

 

Contact:

For scientific enquiries please contact [email protected]

For general enquiries please contact [email protected] or visit www.emmac.co m  

CAUTIONARY STATEMENT

All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

ENDS

 

For further information on the Company please visit www.fstfwd.co   or contact:

Ed McDermott / Lance de Jersey

FastForward Innovations Ltd

Email: [email protected]  

 

James Biddle / Roland Cornish

Beaumont Cornish Limited,

Nomad

 

Tel: +44 (0) 207 628 3396

 

Isabella Pierre / Damon Heath

Shard Capital Partners LLP

 

Tel: (0)207 186 9927

Isabel de Salis / Beth Melluish

St Brides Partners Ltd,

Financial PR

Tel: +44 (0)207 236 1177

 

Notes

FastForward Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASEFFMMEFSEFF